Senseonics Holdings
Update in progressSENS (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Devices
Senseonics Holdings, Inc. is a commercial-stage medical technology company focused on developing and manufacturing continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its implantable CGM platforms—Eversense, Eversense XL, Eversense E3, and Eversense 365—use an under-skin sensor, a removable rechargeable transmitter, and a mobile app for real-time glucose monitoring and management. The company serves providers and patients through distributors and partners. Founded in 1996, it is headquartered in Germantown, Maryland.
Company score
- Sentiment
- 0.32
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.02
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.26
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.21
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!